Profound Medical
- Home ›
- CA ›
- Healthcare
Profound Medical Corp. operates as a medical technology company focuses on magnetic resonance guided ablation procedures in Canada, Germany, and Finland. The last earnings update was 73 days ago. More info.
Add to Portfolio Compare Print
- Profound Medical has significant price volatility in the past 3 months.
PRN Share Price and Events
7 Day Returns
1 Year Returns
PRN Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Profound Medical (PRN) | 10.8% | -11.1% | -17.2% | -20.9% | -44.6% | - |
| CA Medical Equipment | -1.4% | -3.7% | -9.3% | -12.9% | -58.1% | -83.5% |
| CA Market | -0.5% | 0.8% | -2.1% | -2.9% | 8% | 0.6% |
1 Year Return vs Industry and Market
- PRN underperformed the Medical Equipment industry which returned -12.9% over the past year.
- PRN underperformed the Market in Canada which returned -2.9% over the past year.
Price Volatility
Related Companies
Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
- It is not possible to calculate the future cash flow value for Profound Medical. This is due to cash flow or dividend data being unavailable. The share price is CA$0.72.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Profound Medical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Profound Medical's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in CAD | CA$-0.17 |
| TSX:PRN Share Price ** | TSX (2019-07-17) in CAD | CA$0.72 |
| North America Medical Equipment Industry PE Ratio | Median Figure of 66 Publicly-Listed Medical Equipment Companies | 41.39x |
| Canada Market PE Ratio | Median Figure of 538 Publicly-Listed Companies | 15.05x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Profound Medical.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = TSX:PRN Share Price ÷ EPS (both in CAD) = 0.72 ÷ -0.17 |
-4.15x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Profound Medical is loss making, we can't compare its value to the North America Medical Equipment industry average.
- Profound Medical is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does
Profound Medical's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -4.15x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts |
14.6%per year |
| North America Medical Equipment Industry PEG Ratio | Median Figure of 56 Publicly-Listed Medical Equipment Companies | 2.26x |
| Canada Market PEG Ratio | Median Figure of 248 Publicly-Listed Companies | 1.16x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Profound Medical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Profound Medical's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in CAD | CA$0.22 |
| TSX:PRN Share Price * | TSX (2019-07-17) in CAD | CA$0.72 |
| Canada Medical Equipment Industry PB Ratio | Median Figure of 16 Publicly-Listed Medical Equipment Companies | 5.35x |
| Canada Market PB Ratio | Median Figure of 2,440 Publicly-Listed Companies | 1.42x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = TSX:PRN Share Price ÷ Book Value per Share (both in CAD) = 0.72 ÷ 0.22 |
3.26x |
* Primary Listing of Profound Medical.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Profound Medical is good value based on assets compared to the CA Medical Equipment industry average.
Value checks
We assess Profound Medical's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check) Profound Medical has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare Profound Medical's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
- Unable to compare Profound Medical's earnings growth to the Canada market average as it is expected to be loss making during the next 1-3 years.
- Profound Medical's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| TSX:PRN Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts | 14.6% |
| TSX:PRN Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts | 47.6% |
| Canada Medical Equipment Industry Earnings Growth Rate | Market Cap Weighted Average | 38.4% |
| Canada Medical Equipment Industry Revenue Growth Rate | Market Cap Weighted Average | 33.8% |
| Canada Market Earnings Growth Rate | Market Cap Weighted Average | 14% |
| Canada Market Revenue Growth Rate | Market Cap Weighted Average | 5.7% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
| Date (Data in CAD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 71 | -19 | 1 | |
| 2022-12-31 | 66 | 18 | -4 | 2 |
| 2021-12-31 | 42 | 7 | -10 | 2 |
| 2020-12-31 | 22 | 0 | -12 | 3 |
| 2019-12-31 | 7 | -17 | -18 | 3 |
| Date (Data in CAD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | 4 | -18 | -19 |
| 2018-12-31 | 3 | -18 | -21 |
| 2018-09-30 | 3 | -19 | -20 |
| 2018-06-30 | 4 | -16 | -21 |
| 2018-03-31 | 5 | -15 | -20 |
| 2017-12-31 | 5 | -15 | -19 |
| 2017-09-30 | 3 | -15 | -19 |
| 2017-06-30 | 2 | -15 | -18 |
| 2017-03-31 | 1 | -15 | -17 |
| 2016-12-31 | -15 | -16 | |
| 2016-09-30 | -11 | -14 | |
| 2016-06-30 | -11 | -13 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
All data from Profound Medical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in CAD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | -0.16 | -0.16 | -0.16 | 1.00 |
| 2022-12-31 | -0.23 | -0.23 | -0.23 | 1.00 |
| 2021-12-31 | -0.24 | -0.24 | -0.24 | 1.00 |
| 2020-12-31 | -0.15 | -0.09 | -0.21 | 2.00 |
| 2019-12-31 | -0.17 | -0.16 | -0.18 | 3.00 |
| Date (Data in CAD Millions) | EPS * |
|---|---|
| 2019-03-31 | -0.17 |
| 2018-12-31 | -0.21 |
| 2018-09-30 | -0.22 |
| 2018-06-30 | -0.26 |
| 2018-03-31 | -0.29 |
| 2017-12-31 | -0.31 |
| 2017-09-30 | -0.35 |
| 2017-06-30 | -0.36 |
| 2017-03-31 | -0.37 |
| 2016-12-31 | -0.39 |
| 2016-09-30 | -0.36 |
| 2016-06-30 | -0.33 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Profound Medical is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
Future performance checks
We assess Profound Medical's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Profound Medical has a total score of 3/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Profound Medical performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Profound Medical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare Profound Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Profound Medical's 1-year growth to the North America Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
All data from Profound Medical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in CAD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | 3.70 | -18.75 | 9.48 | 10.43 |
| 2018-12-31 | 2.60 | -20.76 | 10.75 | 10.27 |
| 2018-09-30 | 2.78 | -20.43 | 10.51 | 9.63 |
| 2018-06-30 | 3.95 | -20.82 | 10.19 | 9.87 |
| 2018-03-31 | 4.69 | -19.65 | 9.10 | 10.30 |
| 2017-12-31 | 4.90 | -18.82 | 9.14 | 9.64 |
| 2017-09-30 | 3.01 | -19.08 | 9.38 | 9.79 |
| 2017-06-30 | 1.55 | -17.62 | 8.40 | 9.40 |
| 2017-03-31 | 0.59 | -16.61 | 7.14 | 9.05 |
| 2016-12-31 | -16.33 | 5.99 | 9.65 | |
| 2016-09-30 | -14.31 | 4.91 | 8.45 | |
| 2016-06-30 | -13.20 | 4.69 | 7.65 | |
| 2016-03-31 | -18.26 | 6.77 | 6.63 | |
| 2015-12-31 | -16.38 | 6.24 | 4.98 | |
| 2015-09-30 | -16.01 | 6.22 | 4.35 | |
| 2015-06-30 | -14.59 | 5.47 | 3.15 | |
| 2015-03-31 | -9.82 | 2.43 | 2.52 | |
| 2014-12-31 | -8.20 | 2.16 | 2.17 | |
| 2013-12-31 | -14.21 | 1.37 | 1.93 | |
| 2012-12-31 | -9.01 | 1.34 | 1.77 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Profound Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Profound Medical has efficiently used its assets last year compared to the North America Medical Equipment industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Profound Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Profound Medical's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Profound Medical has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Profound Medical's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Profound Medical's finances.
The net worth of a company is the difference between its assets and liabilities.
- Profound Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Profound Medical's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 2.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Profound Medical Company Filings, last reported 3 months ago.
| Date (Data in CAD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 23.89 | 11.93 | 27.05 |
| 2018-12-31 | 26.63 | 11.96 | 30.69 |
| 2018-09-30 | 31.11 | 11.79 | 35.21 |
| 2018-06-30 | 36.01 | 3.72 | 32.00 |
| 2018-03-31 | 41.62 | 3.80 | 38.01 |
| 2017-12-31 | 14.14 | 5.15 | 11.10 |
| 2017-09-30 | 18.38 | 5.37 | 16.31 |
| 2017-06-30 | 6.62 | 5.27 | 10.67 |
| 2017-03-31 | 10.83 | 6.92 | 16.89 |
| 2016-12-31 | 14.84 | 6.64 | 20.83 |
| 2016-09-30 | 2.92 | 6.37 | 9.57 |
| 2016-06-30 | 6.85 | 6.11 | 12.97 |
| 2016-03-31 | 10.33 | 5.89 | 16.98 |
| 2015-12-31 | 13.96 | 5.85 | 20.52 |
| 2015-09-30 | 16.66 | 5.61 | 23.28 |
| 2015-06-30 | 19.34 | 5.38 | 25.96 |
| 2015-03-31 | -39.84 | 15.61 | 0.49 |
| 2014-12-31 | -37.94 | 12.49 | 0.41 |
| 2013-12-31 | -27.73 | 9.15 | 0.61 |
| 2012-12-31 | -14.65 | 5.84 | 0.57 |
- Profound Medical's level of debt (49.9%) compared to net worth is high (greater than 40%).
- Profound Medical had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Profound Medical has sufficient cash runway for 1.5 years based on current free cash flow.
- Profound Medical has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 15.4% each year.
Financial health checks
We assess Profound Medical's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Profound Medical has a total score of 5/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Profound Medical's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
CA$2,000 of
Profound Medical
shares you are expected to receive
CA$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Profound Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Profound Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
| North America Medical Equipment Industry Average Dividend Yield | Market Cap Weighted Average of 24 Stocks | 1.2% |
| Canada Market Average Dividend Yield | Market Cap Weighted Average of 336 Stocks | 3.5% |
| Canada Minimum Threshold Dividend Yield | 10th Percentile | 1.1% |
| Canada Bottom 25% Dividend Yield | 25th Percentile | 2.1% |
| Canada Top 25% Dividend Yield | 75th Percentile | 5.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in CA$) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | ||
| 2020-12-31 | ||
| 2019-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Profound Medical has not reported any payouts.
- Unable to verify if Profound Medical's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Profound Medical's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Profound Medical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Profound Medical has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | CA$855,665 |
| AGE | 64 |
| TENURE AS CEO | 2.9 years |
CEO Bio
Dr. Arun Swarup Menawat, Ph.D., MBA, has been the Chief Executive Officer of Profound Medical Corp. since August 15, 2016. Dr. Menawat served as the Chief Executive Officer and President of Novadaq Technologies Inc. since April 2003 until July 6, 2016. Dr. Menawat served as President and Chief Operating Officer of Merge Healthcare Canada Corp., (also known as Cedara Software Corp.) until November 25, 2002. He served as Vice President of Operations at Tenneco Inc., where he introduced 84 new products in a single year. He served as Business Manager and Research & Development Manager at Hercules, Inc. He served as President of Coils. He has spent many years developing a solid understanding of the medical imaging based diagnostic and therapeutic procedures. He serves as the Chairman of the Board at ElMindA Ltd. Dr. Menawat led Stereotaxis, Inc to an IPO in the Canadian TSX and US NASDAQ listing. Dr. Menawat has an accomplished history of executive leadership success in the healthcare industry. He served as the Chairman of Novadaq Technologies Inc. since 2015 until July 6, 2016. He has been a Director of MedCurrent Corporation since March 2014 and Profound Medical Corp. since June 04, 2015. He has been an Independent Director of Stereotaxis, Inc. since September 29, 2016. He served as a Director of Novadaq Technologies Inc., since July 2003 until July 6, 2016. He served as a Director of Mira IV Acquisition Corp. He served as a Director of Cedara Software Corp. Dr. Menawat holds a B.S. in Biology from University of District of Columbia, an M.S. and Ph.D., in Chemical (Bio) Engineering, from the University of Maryland and a fellowship in biomedical engineering from the National Institutes of Health. He also earned an Executive MBA from the J.L. Kellogg School of Management, Northwestern University. In 2014, Dr. Menawat was named the EY Ontario Entrepreneur of the Year in the health sciences category. He also earned an Executive MBA from the J.L. Kellogg School of Management, Northwestern University, Evanston, Illinois.
CEO Compensation
- Arun's compensation has increased whilst company is loss making.
- Arun's remuneration is higher than average for companies of similar size in Canada.
Management Team
Arun Menawat
CEO & Director
CA$856K
64
2.9 yrs
Aaron Davidson
CFO & Senior VP of Corporate Development
CA$1M
51
1.2 yrs
Stephen Kilmer
Investor Relations
Board of Directors Tenure
Average tenure and age of the Profound Medical board of directors in years:
- The tenure for the Profound Medical board of directors is about average.
Board of Directors
Arun Menawat
CEO & Director
CA$856K
64
4.1 yrs
Ken Galbraith
Director
CA$48K
56
2.5 yrs
Eric Klein
Member of Clinical Advisory Board
Jean-François Pariseau
Independent Director
49
4.1 yrs
Peter Albertsen
Member of Clinical Advisory Board
Scott Eggener
Member of Clinical Advisory Board
Adam Kibel
Member of Clinical Advisory Board
Aytekin Oto
Member of Clinical Advisory Board
Ian Thompson
Member of Clinical Advisory Board
Clare Tempany-Afdhal
Member of Clinical Advisory Board
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (CA$) | Value (CA$) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 04. Dec 18 | Buy | Arun Menawat | Individual | 03. Dec 18 | 04. Dec 18 | 153,700 | CA$0.69 | CA$102,874 | ||
| 02. Oct 18 | Buy | Ian Heynen | Individual | 28. Sep 18 | 28. Sep 18 | 15,000 | CA$0.72 | CA$10,800 | ||
| 02. Oct 18 | Buy | Aaron Davidson | Individual | 28. Sep 18 | 28. Sep 18 | 29,000 | CA$0.72 | CA$20,880 | ||
| 01. Oct 18 | Buy | Aaron Davidson | Individual | 28. Sep 18 | 28. Sep 18 | 6,000 | CA$0.73 | CA$4,380 | ||
| 28. Sep 18 | Buy | Rashed Dewan | Individual | 28. Sep 18 | 28. Sep 18 | 15,000 | CA$0.72 | CA$10,800 | ||
| 28. Sep 18 | Buy | Guruprit Singh | Individual | 28. Sep 18 | 28. Sep 18 | 25,000 | CA$0.72 | CA$18,000 | ||
| 28. Sep 18 | Buy | Arun Menawat | Individual | 28. Sep 18 | 28. Sep 18 | 137,000 | CA$0.72 | CA$99,010 | ||
Management checks
We assess Profound Medical's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Profound Medical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Who Has Been Buying Profound Medical Corp. (TSE:PRN) Shares?
So we'll take a look at whether insiders have been buying or selling shares in Profound Medical Corp. … For example, a Harvard University study found that 'insider purchases earn abnormal returns of more than 6% per year.' View our latest analysis for Profound Medical The Last 12 Months Of Insider Transactions At Profound Medical In the last twelve months, the biggest single purchase by an insider was when CEO & Director Arun Menawat bought CA$103k worth of shares at a price of CA$0.69 per share. … Happily, the Profound Medical insiders decided to buy shares at close to current prices.
Simply Wall St - – Full articleThose Who Purchased Profound Medical (TSE:PRN) Shares Three Years Ago Have A 37% Loss To Show For It
But its virtually certain that sometimes you will buy stocks that fall short of the market average returns. … See our latest analysis for Profound Medical Because Profound Medical is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … So it makes a lot of sense to check out what analysts think Profound Medical will earn in the future (free profit forecasts).
Simply Wall St - – Full articleIs Profound Medical Corp. (TSE:PRN) Excessively Paying Its CEO?
First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Arun Menawat's Compensation Compare With Similar Sized Companies. … is worth CA$95m, and total annual CEO compensation is CA$344k.
Simply Wall St - – Full articleAre Profound Medical Corp.'s (TSE:PRN) Interest Costs Too High?
(TSE:PRN) with its market cap of CA$92m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.
Simply Wall St - – Full articleDid Profound Medical Corp. (TSE:PRN) Insiders Buy Up More Shares?
So shareholders might well want to know whether insiders have been buying or selling shares in Profound Medical Corp. … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … The Last 12 Months Of Insider Transactions At Profound Medical.
Simply Wall St - – Full articleSome Profound Medical Shareholders Are Down 38%
Given that Profound Medical didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … Shareholders of unprofitable companies usually expect strong revenue growth. … That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.
Simply Wall St - – Full articleDoes The Profound Medical Corp. (TSE:PRN) Share Price Fall With The Market?
Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Some stocks mimic the volatility of the market quite closely, while others demonstrate muted, exagerrated or uncorrelated price movements. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility).
Simply Wall St - – Full articleWhat Kind Of Investor Owns Most Of Profound Medical Corp. (TSE:PRN)?
Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … Profound Medical is a smaller company with a market capitalization of CA$72m, so it may still be flying under the radar of many institutional investors. … institutional investors have bought into the company.
Simply Wall St - – Full articleIs Profound Medical Corp.'s (TSE:PRN) Balance Sheet Strong Enough To Weather A Storm?
While small-cap stocks, such as Profound Medical Corp. … (TSE:PRN) with its market cap of CA$64m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. … Companies operating in the Medical Equipment industry,.
Simply Wall St - – Full articleProfound Medical Corp (TSE:PRN): Exploring Free Cash Flows
I will take you through Profound Medical’s cash flow health and the risk-return concept based on the stock’s cash flow yield, using the most recent financial data. … Profound Medical generates cash through its day-to-day business, which needs to be reinvested into the company in order for it to continue operating. … I will be analysing Profound Medical’s FCF by looking at its FCF yield and its operating cash flow growth.
Simply Wall St - – Full articleCompany Info
Description
Profound Medical Corp. operates as a medical technology company focuses on magnetic resonance guided ablation procedures in Canada, Germany, and Finland. It is developing a treatment to ablate the prostate gland in prostate cancer patients, treatment of uterine fibroids and nerves, and palliative pain treatment for patients with metastatic bone disease. The company is headquartered in Mississauga, Canada.
Details
| Name: | Profound Medical Corp. |
| PRN | |
| Exchange: | TSX |
| Founded: | |
| CA$77,812,516 | |
| 108,072,939 | |
| Website: | http://www.profoundmedical.com |
| Address: |
Profound Medical Corp. 2400 Skymark Avenue, Unit 6, Mississauga, Ontario, L4W 5K5, Canada |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| TSX | PRN | Common Shares | The Toronto Stock Exchange | CA | CAD | 05. Jun 2015 | |
| OTCPK | PRFM.F | Common Shares | Pink Sheets LLC | US | USD | 05. Jun 2015 |
Number of employees
Current staff
Industry
| Health Care Equipment | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/07/18 01:03 |
| End of day share price update: | 2019/07/17 00:00 |
| Last estimates confirmation: | 2019/07/15 |
| Last earnings filing: | 2019/05/06 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
